Dr. Hendrickson is a pulmonary and critical care medicine subspecialist with an expertise and research focus in acute lung injury and acute respiratory distress syndrome (ARDS), the most common life-threatening manifestation of COVID-19 disease. She is the co-medical director of the Medical Intensive Care Unit at Zuckerberg San Francisco General Hospital, the safety-net hospital for our county that has cared for approximately half of all ICU patients with COVID-19 disease in San Francisco. Dr. Hendrickson serves as the physician lead to establish and run the newly established COVID ICU.

COVID-19 Related Research Efforts:
As an ARDS translational researchers and the Co-Medical Director of the Intensive Care Unit at Zuckerberg San Francisco General Hospital (ZSFG), Dr. Hendrickson pivoted her research endeavors to study COVID-19 disease with a specific interest in pneumonia and ARDS. She is the site principal investigator for two important COVID-19- related studies:
1. STAT Trial - a randomized clinical trial sponsored by the Department of Defense testing mesenchymal stromal cells for ARDS that primarily enrolls critically ill patients with ARDS
from COVID-19
2. COMET Study- a longitudinal cohort study of hospitalized patients with COVID-19 disease with biospecimen collection sponsored by the National Institute of Health (https://www.comet-study.org). She is also the Clinical Operations Lead and a member of the Executive Committee for the
COMET study.

Additionally, Dr. Hendrickson is a co-investigator on two other COVID-19-related randomized controlled clinical trials: one testing COVID-19 convalescent plasma for patients with COVID-19 pneumonia, the CAPRI study, and a second comparing two anticoagulation strategies for hospitalized patients with SARS-CoV-2 infection, ACTIV-4.